Drugmakers
Latest news and updates related to drugmakers
About Drugmakers coverage
The Drugmakers news hub on Global Investing News tracks breaking headlines that matter to investors, policy watchers, and market strategists. Use this page to monitor how Drugmakers developments affect earnings expectations, sector rotation, supply chains, regulation, and cross-asset volatility. Stories are grouped by source type — market data, company announcements, regulatory filings, and expert analysis — so you can scan the signal quickly without wading through duplicate wire copy. When a headline links to a full article, you will find expanded context, key facts, and prediction-market angles where available. Bookmark this hub if you follow Drugmakers across quarters; new items are added as our crawl pipeline ingests fresh sources throughout the trading day.
Explore related topics
Latest Drugmakers headlines
Other Sources
(4)Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite
European pharmaceutical giants Roche (RHHBY) and Sanofi (SNY) reported earnings that largely fell flat against analyst expectations, shifting investor focus from current financials to future drug pipelines. For Roche, the decline in COVID-related diagnostic sales continues to weigh on year-over-year comparisons, but the company is aggressively pivoting toward its oncology and neurology portfolio to offset patent cliffs for legacy blockbusters. Sanofi face similar pressure, with investors scrutinizing the company's ability to diversify revenue away from its flagship immunology drug, Dupixent. The muted market reaction reflects a broader trend in the pharmaceutical sector where 'growth excellence' is being prioritized over steady-state earnings, especially as US drug price negotiations under the Inflation Reduction Act loom large. Both companies are currently in a transition phase, utilizing robust cash flows to fund R&D and strategic acquisitions. Investors should closely monitor upcoming clinical trial readouts, specifically Roche’s late-stage Alzheimer’s data and Sanofi’s expansion into chronic obstructive pulmonary disease (COPD). The long-term thesis for these stocks relies on 'pipeline de-risking' rather than immediate quarterly EPS beats, as high interest rates continue to favor companies with clear, proprietary innovation cycles over those relying on generic-facing legacy portfolios.
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
The weight-loss drug market, currently dominated by injectable GLP-1 agonists like Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, is entering a critical second phase of evolution. Pharmaceutical giants are pivoting toward oral formulations (pills) to address the primary barriers to adoption: 'needle phobia' and complex cold-chain logistics. By shifting to pills, manufacturers can significantly lower production costs and expand access to primary care settings, potentially tapping into a broader patient demographic beyond the current supply-constrained elite market. Furthermore, the industry is moving toward 'GLP-1 plus' combinations—testing drugs that pair weight loss with muscle preservation or cardiovascular benefits—to improve the quality of weight loss. For investors, this represents a shift from a 'land grab' phase to a 'differentiation' phase. As competition intensifies from challengers like Viking Therapeutics and Roche, the incumbents' ability to defend their moat will depend on their oral pipelines and the results of long-term outcome trials. Investors should watch for upcoming Phase 3 data on oral semaglutide and orforglipron, as these results will likely dictate market share leadership through 2030.
Buyout Wave Seen Among Japan Drugmakers After Hisamitsu Deal
Following Hisamitsu Pharmaceutical Co.'s agreement to acquire Noven Pharmaceuticals Inc., analysts are predicting an increase in mergers and acquisition activity within the Japanese pharmaceutical sector. This trend is driven by Japanese drugmakers seeking to expand their global reach and product portfolios through strategic purchases of foreign rivals, especially as domestic growth opportunities may be limited.
Trump 'Thrilled' to Announce Deals With Nine Drugmakers
Former President Donald Trump announced that his administration had secured deals with nine pharmaceutical companies to provide cheaper prescription drugs. These agreements, made during his presidency, aim to lower drug costs for Medicare beneficiaries and were a key part of his healthcare agenda at the time.
Get alerts for this topic
Subscribe to receive updates about "Drugmakers"